Introduction
Hemorrhagic cystitis (HC) is a relatively common and potentially severe complication observed after high-dose chemoradiotherapy, especially in conjunction with hematopoietic stem cell transplantation (HSCT). Differences in definition criteria are in part responsible for the wide range of reported incidence, which depends upon such factors as the conditioning regimen, type of transplant and the presence of acute graft-versus-host disease (GVHD). 1, 2 The spectrum of clinical presentations varies from asymptomatic microhematuria to life-threatening bleeding. Moreover, the formation of blood clots can lead to hydronephrosis and renal failure. 3 Early presentation of HC is mainly caused by direct toxicity of the conditioning regimen to the uroepithelium, while viral reactivation contributes to the pathogenesis of late onset HC. 4, 5 Many therapeutic modalities have been tested in the treatment of established HC refractory to supportive measures, but none of them has been proved to be effective to date. Sodium hyaluronate is a glycosaminoglycan present on the bladder mucosa, which serves as an important protective substance against uroepithelial damage. Preparations of this component have been shown to be effective in the treatment of interstitial cystitis 6, 7 including post-chemoradiotherapy induced interstitial cystitis. 8 In this study, we tested the efficacy and safety of sodium hyaluronate in a cohort of seven patients with posttransplant HC.
Patients and methods

Patient characteristics
All the patients who underwent HSCT between December 2004 and November 2005 at the Department of Bone Marrow Transplantation of Hadassah -Hebrew University Hospital and developed HC gradeX2, were included in this study. All patients or their guardians signed an approved informed consent. Patient characteristics are shown in Table 1 . Two of the patients had undergone a previous HSCT, and one of them had a previous episode of HC. Patients transplanted from haploidentical family members received T-cell depleted grafts. Unmanipulated graft and post-transplant anti-GVHD prophylaxis with cyclosporine alone (3 mg/kg/day) was used in all patients transplanted from matched siblings. Patients treated with cyclophosphamide during conditioning received HC prophylaxis, which consisted of: hyperhydratation, forced diuresis and mesna. Before transplantation, all patients received, acyclovir (500 mg/m 2 Â 3/day) from days À8 until day þ 100. Cytomegalovirus (CMV) reactivation (diagnosed by two successive positive PCRs or one positive CMV pp65 antigenemia) were treated with ganciclovir 10 mg/kg/day.
Definitions
HC was defined as the presence of macroscopic hematuria in the absence of other conditions such as gynecologicalrelated bleeding, nephrolithiasis and/or bacterial or fungal infection of the lower urinary tract. 1 HC was classified as early-onset if the symptoms appeared during the first week after transplantation, while HC was characterized as lateonset if the symptoms appeared after the first 7 days. Urine cultures for bacterial and fungal pathogens were obtained from all patients during the episode of hematuria.
Severity of HC was graded according to the following criteria: I: microscopic hematuria. II: macroscopic hematuria. III: macroscopic hematuria with the presence of clots and/or decrease in hemoglobin levels necessitating blood transfusions. IV: life-threatening bleeding, not responding to treatment and necessitating surgical intervention. 9 Response to treatment was defined as follows: initial response was defined as the day upon amelioration of symptoms appeared; complete response was defined as the day in which disappearance of all symptoms including macroscopic hematuria, dysuria, etc. Disappearance of clots with decrease in blood transfusion requirements but with persistence of macroscopic hematuria was defined as partial response (PR). Any other response was considered as no response.
HC treatment
All patients who developed hematuria were initially managed with hyperhydratation and forced diuresis. When indicated, continuous bladder irrigation with saline was performed for prevention of clotting formation. Irradiated leuko-depleted red blood cell and platelet transfusion were given to maintain the hemoglobin level and platelet count above 8 g/l and 40 Â 10 9 /l, respectively.
Sodium hyaluronate treatment program
Sodium hyaluronate (Cystistat, Bioniche Teo, ON, Canada) was a gift from Medison Pharma Ltd, Israel.
Method of sodium hyaluronate administration: 40 mg of sodium hyaluronate in 50 ml (one container) was slowly instilled into the bladder through a Foley catheter. When all the solution had been instilled the catheter was clamped and the sodium hyaluronate was kept in place for a minimum of 20 min as performed in interstitial cystitis treatment. In the event of no response 7 days after the first instillation of sodium hyaluronate, a second course of treatment was given. Bladder irrigation (if performed) was usually resumed following drug administration only when urine excretion was decreased due to clot formation.
Results
Incidence of cystitis
Seven out of a total of 123 patients who underwent HSCT at our institution during the study period, developed clinically significant hemorrhagic cystitis and were included in this study. The median time to onset of the HC was 30 days, range (4-66) after transplantation. One patient developed early onset HC (day 4 after HSCT), while six developed late-onset HC (range, 12-66 days after HSCT). All the seven patients developed moderate to severe (grade III) HC. Urine cultures for detection of adenovirus were performed in three patients and were negative in all three of them. Details are shown in Table 2 .
Treatment before sodium hyaluronate All the patients were initially treated with hyperhydration, forced diuresis and red cell and platelet transfusion support. Three out of seven patients needed continuous bladder irrigation because of massive clot formation and urine retention. The urine cultures for bacterial or fungus were negative in all the cases. Details are shown in Table 2 .
Treatment with sodium hyaluronate Sodium hyaluronate instillation was initiated at a median of 3 days, range (2-7) after development of the symptoms of HC. Three out of seven patients received a second course of treatment because of inadequate response 7 days after the first instillation of sodium hyaluronate. None of the patients developed local or systemic adverse reactions attributable to the treatment.
Response to treatment
Four out of seven patients achieved an initial response during the first 7 days after treatment with sodium Table 2 .
Discussion
Hemorrhagic cystitis, characterized by the presence of hematuria due to diffuse inflammation of the bladder mucosa, is a well-known complication of HSCT. 4 The overall incidence of HC has been reported with a wide range of 7-68%. 1 The clinical manifestations of this disorder vary from microscopic hematuria to severe hemorrhage with clot formation and urinary tract obstruction, leading to hydronephrosis and acute renal failure. HC may result in prolonged hospitalization after HSCT, and can be associated with severe morbidity and mortality. 3, 9 Several factors have been associated with an increased incidence of HC, such as male sex, inclusion of cyclophosphamide and/or busulfan in the conditioning regimen, previous bladder irradiation, allogeneic (vs autologous) SCT, matched unrelated donor transplantation and development of grade II-IV acute GVHD. 2, 10, 11 Depending on the time of presentation, HC can be divided into earlyonset (which occurs mainly during the first week after transplantation) and late-onset. Early-onset HC is usually the result of the uroepithelial damage caused by the conditioning regimen, and in most cases is a transient and self-limiting disorder. High-dose cyclophosphamide is a well-known risk factor associated with the development of HC. It is believed that the uroepithelial damage following cyclophosphamide administration is mainly induced by acrolein which is a metabolic product of cyclophosphamide. 12 In contrast, late-onset HC can be a severe, protracted and potentially life-threatening disorder, and is usually provoked by other triggers, including reactivation of different viruses such as polyoma virus BK, adenovirus, etc. 13, 14 However, the exact pathogenetic mechanisms that result in the development of HC remain largely unknown. In a recent review, Leung et al., classified HC in pre-engrafment and post-engrafment subtypes. They suggested that immune reactions play a significant role in the pathogenesis of post-engraftment BK-associated HC. Initially, the toxicity to the uroepithelium and the immunosupression caused by the conditioning regimen provide suitable conditions for BK viral replication. Finally, hematopoietic reconstitution leads to immunological reaction against viral antigens expressed on the uroepithelium, causing extensive mucosal damage and hemorrhage. 4 Even though HC is a frequent and potentially lifethreatening complication of HSCT, no effective treatment currently exists. Episodes of mild hematuria are usually treated with fluid administration and forced diuresis. When the course is complicated by the formation of clots, intermittent or continuous bladder irrigation may be required. In cases of severe persistent HC many different treatment modalities have been tested. However, the accumulated experience is based on a limited number of patients. 15 Intravesical 1% alumin irrigation represents an effective and a rather well-tolerated treatment for patients with HC associated with bladder carcinoma and irradiation. However, the available data on the use of alumin for patients with post-transplant HC are limited. Moreover, systemic accumulation of alumin in patients with renal failure may provoke severe neurotoxicity (encephalopathy, dementia, convulsions). Also, it is known that alumin salts can cause severe allergic reactions in susceptible individuals even after topical use. 16, 17 Formalin instillation, one of the most effective treatments for severe HC, requires general anesthesia and is associated with important long-term complications including fibrosis of the bladder, urinary incontinence, papillary necrosis, vesicouretheral reflux and urinary tract obstruction with hydronephrosis. 18, 19 Prostaglandins have been reported to have some beneficial effects when administered intravesically. However, prostaglandin administration has been tested in small groups of patients and may cause severe bladder spasm. [20] [21] [22] Intravenous or intravesical administration of cidofovir has been used in cases of adenovirus associated HC. However, the efficacy of this antiviral agent against HC needs to be further investigated. 23, 24 Hyperbaric oxygen therapy has been shown to be effective for HC due to chemotherapy and/ or radiation therapy, and two cases of life-threatening late-onset HC after allogeneic BMT in children, which resolved after treatment with hyperbaric oxygen have been reported. 25 Surgical interventions such as cystectomy, nephrostomy, ureterostomy are associated with high rates of morbidity and mortality and are indicated for life- 27, 28 Sodium hyaluronate (a member of glycosaminoglycans), is a major component of the extracellular matrix of most tissues. High concentration of glucosaminoglycans are present in the uroepithelium, and constitute a protective barrier against irritating agents that can potentially cause damage to epithelium. 29, 30 Sodium hyaluronate has been developed to temporarily replenish the deficient glycosaminglycan layer of the bladder mucosa. It has been used in the treatment of patients with interstitial cystitis with beneficial results. 6 The mechanisms of action of sodium hyaluronate in this setting are not well understood. Sodium hyaluronate has many biological activities, which include inhibition of immune complexes, adherence to polymorphonuclear cells, inhibition of leukocyte migration, regulation of fibroblast and endothelial cell proliferation, enhancement of connective tissue healing, etc. 31 Based on the different mechanisms of action of sodium hyaluronate, and the known efficacy in the setting of interstitial cystitis, we decided to test the efficacy of a similar approach in patients with post-transplant HC.
We consider that the results of our study are promising and the efficacy of sodium hyaluronate in the treatment of post-transplant HC should be further investigated in larger cohorts of patients.
